We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.


Sell:$233.95 Buy:$233.97 Change: $2.91 (1.26%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Change: $2.91 (1.26%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
Change: $2.91 (1.26%)
Market closed |  Prices as at close on 17 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Contact details

One Becton Drive
United States
+1 (201) 8476800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$65.34 billion
Shares in issue:
290.39 million
Health Care Equipment
New York Stock Exchange
United States
US dollar

Key personnel

  • Thomas Polen
    Chairman of the Board, President, Chief Executive Officer
  • Christopher DelOrefice
    Chief Financial Officer, Executive Vice President
  • Shana Neal
    Chief People Officer, Executive Vice President
  • Antoine Ezell
    Executive Vice President, President, North America, Chief Marketing Officer
  • Michelle Quinn
    Executive Vice President, General Counsel
  • Richard Byrd
    Executive Vice President, President - Interventional Segment
  • Michael Garrison
    Executive Vice President, President - Medical Segment
  • Roland Goette
    Executive Vice President, President - EMEA
  • Pavan Mocherla
    Executive Vice President, President, Greater Asia
  • David Shan
    Executive Vice President, Chief Integrated Supply Chain Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.